(Q39990587)

16 September 2017

title

Implications of EGFR inhibition in ovarian cancer cell proliferation (English)

1 reference

16 September 2017

1 reference

6

David S Miller

1 reference

16 September 2017

Shawna L Bull Phelps

1

1 reference

16 September 2017

John O Schorge

2

1 reference

16 September 2017

Michael J Peyton

3

1 reference

16 September 2017

Hisayuki Shigematsu

4

1 reference

16 September 2017

Li-Lin Xiang

5

1 reference

16 September 2017

Jayanthi S Lea

7

1 reference

16 September 2017

language of work or name

English

0 references

publication date

1 June 2008

1 reference

16 September 2017

1 reference

16 September 2017

volume

109

1 reference

16 September 2017

issue

3

1 reference

16 September 2017

page(s)

411-417

1 reference

Effect of Epidermal Growth Factor Receptor Expression Level on Survival in Patients with Epithelial Ovarian Cancer

16 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Targeting targeted therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Species differences in renal Src activity direct EGF receptor regulation in life or death response to EGF.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Gefitinib versus cetuximab in lung cancer: round one.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

The when and how of Src regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Subsets of epidermal growth factor receptors during activation and endocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

cbl-b inhibits epidermal growth factor receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Controlling epidermal growth factor (EGF)-stimulated Ras activation in intact cells by a cell-permeable peptide mimicking phosphorylated EGF receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

The HER4 cytoplasmic domain, but not its C terminus, inhibits mammary cell proliferation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa").

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Developing inhibitors of the epidermal growth factor receptor for cancer treatment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Role of TGF alpha stimulation of the ERK, PI3 kinase and PLC gamma pathways in ovarian cancer growth and migration.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

Expression of epidermal growth factor receptor in normal ovary and in ovarian tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.02.030

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2008.02.030

1 reference

16 September 2017

1 reference